Ironwood Pharmaceuticals ...

0.66
-0.29 (-30.20%)
At close: Apr 14, 2025, 12:51 PM
-30.20%
Bid 0.66
Market Cap 106.57M
Revenue (ttm) 351.41M
Net Income (ttm) 28.33M
EPS (ttm) 0.01
PE Ratio (ttm) 65.86
Forward PE 17.88
Analyst Buy
Ask 0.7
Volume 7,971,198
Avg. Volume (20D) 3,390,798
Open 0.71
Previous Close 0.95
Day's Range 0.59 - 0.73
52-Week Range 0.59 - 8.45
Beta 0.30

About IRWD

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European...

Sector Healthcare
IPO Date Feb 3, 2010
Employees 253
Stock Exchange NASDAQ
Ticker Symbol IRWD
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for IRWD stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 1418.37% from the latest price.

Stock Forecasts

Next Earnings Release

Ironwood Pharmaceuticals Inc. is scheduled to release its earnings on May 8, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-38.17%
Ironwood Pharmaceuticals shares are trading lower.... Unlock content with Pro Subscription
2 months ago
-2.11%
Ironwood Pharmaceuticals shares are trading lower. The company board announced approval for a 50% reduction in the workforce.